All In Biotech

Drug Trial Radar · NCT07235293

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jan 16, 2026

Primary completion

Sep 30, 2026

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Kahr Bio Australia Pty LtdIndustry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Conditions

  • Colorectal Cancer

Interventions

  • DSP107 + AtezolizumabDrug

    DSP107 infusion begins \~30 (±10) minutes after completion of atezolizumab infusion on Day 1.

  • FruquintinibDrug

    5 mg orally, once daily (with or without food), on Days 1-21 of each 28-day cycle, followed by 7 days off.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine Median overall survival (mOS) in participants treated with the combination of DSP107 and atezolizumab versus fruquintinib.Time frame: From Day 1 until date of death from any cause assessed up to 2 years

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP)

    Aurora, Colorado · Recruiting

  • University of Colorado Cancer Center - Highlands Ranch Hospital

    Highlands Ranch, Colorado · Recruiting

  • Mayo Clinic

    Florida City, Florida · Recruiting

  • Duke University Medical Center - Duke Cancer Center

    Durham, North Carolina · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Texas City, Texas · Recruiting

  • The Queen Elizabeth Hospital

    Woodville, Adelaide, Australia · Recruiting

  • Chris O'brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Port Macquarie Base Hospital (Mid North Coast Cancer Institute), Wrights Road,

    Port Macquarie, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Icon Cancer Centre

    South Brisbane, Queensland, Australia · Recruiting

  • Flinders Medical Centre SA

    Bedford Park, South Australia, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Footscray Hospital - Western Health

    Footscray, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Sunshine Hospital - Western Health

    Saint Albans, Victoria, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.